Literature DB >> 25003312

Considerations for combined immune checkpoint modulation and radiation treatment.

Steven C Almo1, Chandan Guha.   

Abstract

Recent advances indicate that new therapeutic strategies for the treatment of malignancies will be realized from combined radiation treatment and immune checkpoint modulation. Numerous biophysical properties must be considered for effective biologic development, including affinity, selectivity, oligomeric state and valency. High-resolution structural characterization contributes to our understanding of these properties and can lead to the realization of proteins with unique in vitro activities and novel in vivo therapeutic functions. In this article we focus on the importance of these factors for new potential biologics and consider these in the context of combination therapies with physical modalities, including radiation therapy. In particular, we examine the consequences of altered avidities and subset-specific ligand density on the rational modification of biological function in the immunoglobulin and tumor necrosis factor superfamilies and for new optimized combination therapies.

Entities:  

Mesh:

Year:  2014        PMID: 25003312      PMCID: PMC4163026          DOI: 10.1667/RR13667.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  56 in total

1.  Costimulation blockade with belatacept in renal transplantation.

Authors:  Vikas R Dharnidharka
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

2.  Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

Authors:  Christian P Larsen; Thomas C Pearson; Andrew B Adams; Paul Tso; Nozomu Shirasugi; Elizabeth Strobert; Dan Anderson; Shannon Cowan; Karen Price; Joseph Naemura; John Emswiler; JoAnne Greene; Lori Ann Turk; Jurgen Bajorath; Robert Townsend; David Hagerty; Peter S Linsley; Robert J Peach
Journal:  Am J Transplant       Date:  2005-03       Impact factor: 8.086

3.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 4.  Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.

Authors:  Léia C R Silva; Luciena C M Ortigosa; Gil Benard
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

5.  T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell.

Authors:  Pablo A González; Leandro J Carreño; Daniel Coombs; Jorge E Mora; Edith Palmieri; Byron Goldstein; Stanley G Nathenson; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-16       Impact factor: 11.205

6.  "Peptabody": a new type of high avidity binding protein.

Authors:  A V Terskikh; J M Le Doussal; R Crameri; I Fisch; J P Mach; A V Kajava
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

7.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Authors:  Mark C Genovese; Jean-Claude Becker; Michael Schiff; Michael Luggen; Yvonne Sherrer; Joel Kremer; Charles Birbara; Jane Box; Kannan Natarajan; Isaac Nuamah; Tracy Li; Richard Aranda; David T Hagerty; Maxime Dougados
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

8.  Costimulation blockade with belatacept in renal transplantation.

Authors:  Flavio Vincenti; Christian Larsen; Antoine Durrbach; Thomas Wekerle; Björn Nashan; Gilles Blancho; Philippe Lang; Josep Grinyo; Philip F Halloran; Kim Solez; David Hagerty; Elliott Levy; Wenjiong Zhou; Kannan Natarajan; Bernard Charpentier
Journal:  N Engl J Med       Date:  2005-08-25       Impact factor: 91.245

9.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

Authors:  Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

10.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

View more
  4 in total

1.  Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Authors:  Udupi A Ramagopal; Weifeng Liu; Sarah C Garrett-Thomson; Jeffrey B Bonanno; Qingrong Yan; Mohan Srinivasan; Susan C Wong; Alasdair Bell; Shilpa Mankikar; Vangipuram S Rangan; Shrikant Deshpande; Alan J Korman; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

2.  Immunobiology of radiotherapy: new paradigms.

Authors:  Mansoor M Ahmed; Chandan Guha; James W Hodge; Elizabeth Jaffee
Journal:  Radiat Res       Date:  2014-07-18       Impact factor: 2.841

3.  Template-assisted 192Ir-based stereotactic ablative brachytherapy as a neoadjuvant treatment for operable peripheral non-small cell lung cancer: a phase I clinical trial.

Authors:  Xiang-Xiang Shi; Hao-Wen Pang; Pei-Rong Ren; Xiao-Yang Sun; Jing-Bo Wu; Sheng Lin
Journal:  J Contemp Brachytherapy       Date:  2019-04-29

4.  The CC' loop of IgV domains of the immune checkpoint receptors, plays a key role in receptor:ligand affinity modulation.

Authors:  Shankar V Kundapura; Udupi A Ramagopal
Journal:  Sci Rep       Date:  2019-12-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.